Skip to main content

Telix Pharmaceuticals

Telix Pharmaceuticals Ltd is an Australian commercial-stage biopharmaceutical company specializing in radiopharmaceuticals for cancer imaging and therapy. The company develops, manufactures, and markets targeted radiotheranostic products, including its flagship prostate cancer imaging agent Illuccix. Main revenue drivers stem from commercial sales of diagnostic radiopharmaceuticals, alongside clinical trial collaborations and development milestone payments. Telix Pharmaceuticals serves nuclear medicine centers, urologists, oncologist specialists, and hospital diagnostic departments across North America, Europe, and Asia-Pacific. The company holds a market-leading position in prostate-specific membrane antigen targeted radiopharmaceutical imaging. Headquartered in Melbourne, Australia, Telix Pharmaceuticals Ltd is listed on the Australian Securities Exchange and the Nasdaq Stock Market.

4 of the funds FundTelligence covers report a position in Telix Pharmaceuticals.

Legal name
Telix Pharmaceuticals Ltd
Sector
Health Care
Country
Australia
Funds holding it
4

Funds holding Telix Pharmaceuticals

Loading...